Dyne Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Dyne Therapeutics, Inc. (DYN) had Debt Securities, Available-for-sale, Amortized Cost of $222.71 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-07-29
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $222.71M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $219.19M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $216.72M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $217.78M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $222.71M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $219.19M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $216.72M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $217.78M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $198.63M 10-Q · filed 2025-07-28 |
| 2025-03-31 | $205.00M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $206.81M 10-K · filed 2026-03-02 |
| 2024-09-30 | $191.03M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $170.87M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $181.64M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.47M 10-K · filed 2025-02-27 |
| 2023-09-30 | $27.56M 10-Q · filed 2023-10-30 |
| 2023-06-30 | $40.18M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $57.30M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $84.44M 10-K · filed 2024-03-05 |
| 2022-09-30 | $104.22M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $157.01M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $176.12M 10-Q · filed 2022-05-02 |
| 2021-12-31 | $176.01M 10-K · filed 2023-03-02 |
| 2021-09-30 | $178.51M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $177.25M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $172.20M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $44.49M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |